RIZZO, ALESSANDRO
RIZZO, ALESSANDRO
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
2024 Brandi G.; Relli V.; Deserti M.; Palloni A.; Indio V.; Astolfi A.; Serravalle S.; Mattiaccio A.; Vasuri F.; Malvi D.; Deiana C.; Pantaleo M.A.; Cescon M.; Rizzo A.; Katoh M.; Tavolari S.
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents
2022 Rizzo A.; Oderda M.; Mollica V.; Merler S.; Morelli F.; Fragomeno B.; Taveri E.; Sorgentoni G.; Santoni M.; Massari F.
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study
2022 Rizzo A.; Mollica V.; Marchetti A.; Nuvola G.; Rosellini M.; Tassinari E.; Molina-Cerrillo J.; Myint Z.W.; Buchler T.; Monteiro F.S.M.; Grande E.; Santoni M.; Massari F.
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis
2022 Santoni M.; Massari F.; Rizzo A.; Mollica V.; Cimadamore A.; Montironi R.; Battelli N.
Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: A meta-analysis
2022 Rizzo A.; Mollica V.; Santoni M.; Massari F.
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials
2022 Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G.
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw
2022 Mollica V.; Nuvola G.; Tassinari E.; Nigro M.C.; Marchetti A.; Rosellini M.; Rizzo A.; Errani C.; Massari F.
Cabozantinib for Treatment of Brain Metastases in Patients with Renal Cell Carcinoma
2022 Rizzo A.; Mollica V.; Massari F.
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors
2022 Santoni M.; Massari F.; Bracarda S.; Grande E.; Matrana M.R.; Rizzo M.; De Giorgi U.; Basso U.; Aurilio G.; Incorvaia L.; Martignetti A.; Molina-Cerrillo J.; Mollica V.; Rizzo A.; Battelli N.
Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer
2022 Rizzo A.; Mollica V.; Santoni M.; Massari F.
Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis
2022 Rizzo A.; Mollica V.; Santoni M.; Massari F.
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
2022 Viscardi G.; Tralongo A.C.; Massari F.; Lambertini M.; Mollica V.; Rizzo A.; Comito F.; Di Liello R.; Alfieri S.; Imbimbo M.; Della Corte C.M.; Morgillo F.; Simeon V.; Lo Russo G.; Proto C.; Prelaj A.; De Toma A.; Galli G.; Signorelli D.; Ciardiello F.; Remon J.; Chaput N.; Besse B.; de Braud F.; Garassino M.C.; Torri V.; Cinquini M.; Ferrara R.
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma
2022 Mollica V.; Santoni M.; Matrana M.R.; Basso U.; De Giorgi U.; Rizzo A.; Maruzzo M.; Marchetti A.; Rosellini M.; Bleve S.; Maslov D.; Tawagi K.; Philon E.; Blake Z.; Massari F.
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
2022 Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, Andrea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi
Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis
2022 Rizzo A.; Mollica V.; Massari F.
Genomics and Immunomics in the Treatment of Urothelial Carcinoma
2022 Mollica V.; Massari F.; Rizzo A.; Ferrara R.; Menta A.K.; Adashek J.J.
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
2022 Di Federico A.; Mosca M.; Pagani R.; Carloni R.; Frega G.; De Giglio A.; Rizzo A.; Ricci D.; Tavolari S.; Di Marco M.; Palloni A.; Brandi G.
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
2022 Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De Giglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco, Andrea Palloni, Giovanni Brandi.
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: A meta-analysis
2022 Rizzo A.; Mollica V.; Santoni M.; Ricci A.D.; Gadaleta-Caldarola G.; Montironi R.; Massari F.
Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis
2022 Rizzo A.; Mollica V.; Merler S.; Morelli F.; Sorgentoni G.; Oderda M.; Santoni M.; Massari F.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies | Brandi G.; Relli V.; Deserti M.; Palloni A.; Indio V.; Astolfi A.; Serravalle S.; Mattiaccio A.; ...Vasuri F.; Malvi D.; Deiana C.; Pantaleo M.A.; Cescon M.; Rizzo A.; Katoh M.; Tavolari S. | 2024-01-01 | SCIENTIFIC REPORTS | - | 1.01 Articolo in rivista | Brandi_2024.pdf; 41598_2024_52991_MOESM8_ESM.zip |
| A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents | Rizzo A.; Oderda M.; Mollica V.; Merler S.; Morelli F.; Fragomeno B.; Taveri E.; Sorgentoni G.; S...antoni M.; Massari F. | 2022-01-01 | ANTI-CANCER DRUGS | - | 1.01 Articolo in rivista | - |
| Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study | Rizzo A.; Mollica V.; Marchetti A.; Nuvola G.; Rosellini M.; Tassinari E.; Molina-Cerrillo J.; My...int Z.W.; Buchler T.; Monteiro F.S.M.; Grande E.; Santoni M.; Massari F. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | Cancers 2022 [MOUSEION04].pdf; cancers-14-04142-s001.zip |
| Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis | Santoni M.; Massari F.; Rizzo A.; Mollica V.; Cimadamore A.; Montironi R.; Battelli N. | 2022-01-01 | TUMORI | - | 1.01 Articolo in rivista | - |
| Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: A meta-analysis | Rizzo A.; Mollica V.; Santoni M.; Massari F. | 2022-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials | Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G. | 2022-01-01 | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - | 1.01 Articolo in rivista | - |
| Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw | Mollica V.; Nuvola G.; Tassinari E.; Nigro M.C.; Marchetti A.; Rosellini M.; Rizzo A.; Errani C.;... Massari F. | 2022-01-01 | CURRENT ONCOLOGY | - | 1.01 Articolo in rivista | Current Oncology 2022 [Bone agents PCa].pdf |
| Cabozantinib for Treatment of Brain Metastases in Patients with Renal Cell Carcinoma | Rizzo A.; Mollica V.; Massari F. | 2022-01-01 | JAMA ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors | Santoni M.; Massari F.; Bracarda S.; Grande E.; Matrana M.R.; Rizzo M.; De Giorgi U.; Basso U.; A...urilio G.; Incorvaia L.; Martignetti A.; Molina-Cerrillo J.; Mollica V.; Rizzo A.; Battelli N. | 2022-01-01 | EUROPEAN UROLOGY FOCUS | - | 1.01 Articolo in rivista | - |
| Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer | Rizzo A.; Mollica V.; Santoni M.; Massari F. | 2022-01-01 | JOURNAL OF CLINICAL MEDICINE | - | 1.01 Articolo in rivista | Journal Clinical Medicne 2022 [Editorial AR].pdf |
| Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis | Rizzo A.; Mollica V.; Santoni M.; Massari F. | 2022-01-01 | CLINICAL GENITOURINARY CANCER | - | 1.01 Articolo in rivista | - |
| Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis | Viscardi G.; Tralongo A.C.; Massari F.; Lambertini M.; Mollica V.; Rizzo A.; Comito F.; Di Liello... R.; Alfieri S.; Imbimbo M.; Della Corte C.M.; Morgillo F.; Simeon V.; Lo Russo G.; Proto C.; Prelaj A.; De Toma A.; Galli G.; Signorelli D.; Ciardiello F.; Remon J.; Chaput N.; Besse B.; de Braud F.; Garassino M.C.; Torri V.; Cinquini M.; Ferrara R. | 2022-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma | Mollica V.; Santoni M.; Matrana M.R.; Basso U.; De Giorgi U.; Rizzo A.; Maruzzo M.; Marchetti A.;... Rosellini M.; Bleve S.; Maslov D.; Tawagi K.; Philon E.; Blake Z.; Massari F. | 2022-01-01 | TARGETED ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? | Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, An...drea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi | 2022-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis | Rizzo A.; Mollica V.; Massari F. | 2022-01-01 | EUROPEAN UROLOGY FOCUS | - | 1.01 Articolo in rivista | - |
| Genomics and Immunomics in the Treatment of Urothelial Carcinoma | Mollica V.; Massari F.; Rizzo A.; Ferrara R.; Menta A.K.; Adashek J.J. | 2022-01-01 | CURRENT ONCOLOGY | - | 1.01 Articolo in rivista | Current Oncology 2022 [Gen Immuno UC].pdf |
| Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes | Di Federico A.; Mosca M.; Pagani R.; Carloni R.; Frega G.; De Giglio A.; Rizzo A.; Ricci D.; Tavo...lari S.; Di Marco M.; Palloni A.; Brandi G. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | articolo 2022 Immunotherapy in Pancreatic Cancer Why Do We Keep Failing A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes.pdf |
| Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes | Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De G...iglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco, Andrea Palloni, Giovanni Brandi. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-14-02429 (1).pdf |
| Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: A meta-analysis | Rizzo A.; Mollica V.; Santoni M.; Ricci A.D.; Gadaleta-Caldarola G.; Montironi R.; Massari F. | 2022-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis | Rizzo A.; Mollica V.; Merler S.; Morelli F.; Sorgentoni G.; Oderda M.; Santoni M.; Massari F. | 2022-01-01 | EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | - | 1.01 Articolo in rivista | - |